GenSight Biologics Post IPO · $3M raised · (2026)

GenSight Biologics is a biotechnology company advancing gene therapy for neurodegenerative ophthalmic diseases. They are developing treatments for conditions like Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa (RP), and Geographic Atrophy in Dry-AMD, utilizing technologies such as gene therapy, mitochondrial targeting sequences, and optogenetics. Their clinical development includes GS010 (lenadogene nolparvovec) and GS030.